Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod

Fig. 1

Study design of PANGAEA 2.0. The study involves an evaluation of disease activity to identify sub-optimally treated RRMS patients (V0), the switch of MS therapy to fingolimod (Gilenya®; V1), and a 3-year observational phase (V2–V14) to assess treatment response in several functional domains. A sub-study analyzes the benefits of a standardized quantitative evaluation of routine MRI scans by a central reading facility (NEDA-4: No Evidence of Disease Activity-4; 2D FDS: 2D Focused Disability Scale)

Back to article page